Both melanoma cell lines used in the current study have BRAF mutations (Smalley et al., 2008; Boussemart et al., 2014; Fofaria et al., 2015), hence these cell lines could possibly be targeted using a number of drugs such as vemurafnib, dabrafenib, trametinib, or a combination of either these drugs (Jang & Atkins, 2013; Boussemart et al., 2014; Fofaria et al., 2015). This evidence concerns the gene BRAF and melanoma.